Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Urothelial Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Bladder Cancer (143
)
Bladder Cancer (143
)
›
Associations
(248)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
TROP2 positive
Urothelial Cancer
TROP2 positive
Urothelial Cancer
ABN202
Sensitive: D – Preclinical
AACR 2023 - 2 weeks (New D)
ABN202
Sensitive
:
D
AACR 2023 - 2wk
ABN202
Sensitive: D – Preclinical
AACR 2023 - 2 weeks
ABN202
Sensitive
:
D
AACR 2023 - 2 weeks - (New D)
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
avelumab
Sensitive: A1 - Approval
avelumab
Sensitive
:
A1
avelumab
Sensitive: A1 - Approval
avelumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
sacituzumab govitecan-hziy
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
mitomycin urothelial gel
Sensitive: A1 - Approval
mitomycin urothelial gel
Sensitive
:
A1
mitomycin urothelial gel
Sensitive: A1 - Approval
mitomycin urothelial gel
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
enfortumab vedotin
Sensitive: A1 - Approval
enfortumab vedotin
Sensitive
:
A1
enfortumab vedotin
Sensitive: A1 - Approval
enfortumab vedotin
Sensitive
:
A1
FGFR2 mutation
Urothelial Cancer
FGFR2 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
FGFR3 mutation
Urothelial Cancer
FGFR3 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
PD-L1 overexpression
Urothelial Cancer
PD-L1 overexpression
Urothelial Cancer
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
toripalimab
Sensitive: A1 - Approval
toripalimab
Sensitive
:
A1
toripalimab
Sensitive: A1 - Approval
toripalimab
Sensitive
:
A1
FGFR mutation
Urothelial Cancer
FGFR mutation
Urothelial Cancer
erdafitinib
Sensitive: A2 - Guideline
erdafitinib
Sensitive
:
A2
erdafitinib
Sensitive: A2 - Guideline
erdafitinib
Sensitive
:
A2
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
nivolumab + IPI-549
Sensitive: B - Late Trials
nivolumab + IPI-549
Sensitive
:
B
nivolumab + IPI-549
Sensitive: B - Late Trials
nivolumab + IPI-549
Sensitive
:
B
TMB-H
Urothelial Cancer
TMB-H
Urothelial Cancer
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
TMB-H
Urothelial Cancer
TMB-H
Urothelial Cancer
durvalumab
Sensitive: B - Late Trials
durvalumab
Sensitive
:
B
durvalumab
Sensitive: B - Late Trials
durvalumab
Sensitive
:
B
PD-L1 overexpression
Urothelial Cancer
PD-L1 overexpression
Urothelial Cancer
durvalumab
Sensitive: B - Late Trials
durvalumab
Sensitive
:
B
durvalumab
Sensitive: B - Late Trials
durvalumab
Sensitive
:
B
FGFR3 mutation
Urothelial Cancer
FGFR3 mutation
Urothelial Cancer
BAY 1163877
Sensitive: B - Late Trials
BAY 1163877
Sensitive
:
B
BAY 1163877
Sensitive: B - Late Trials
BAY 1163877
Sensitive
:
B
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
avelumab
Sensitive: B - Late Trials
avelumab
Sensitive
:
B
avelumab
Sensitive: B - Late Trials
avelumab
Sensitive
:
B
HER-2 positive
Urothelial Cancer
HER-2 positive
Urothelial Cancer
disitamab vedotin
Sensitive: B - Late Trials
disitamab vedotin
Sensitive
:
B
disitamab vedotin
Sensitive: B - Late Trials
disitamab vedotin
Sensitive
:
B
PD-L1 expression
Urothelial Cancer
PD-L1 expression
Urothelial Cancer
durvalumab
Sensitive: B - Late Trials
durvalumab
Sensitive
:
B
durvalumab
Sensitive: B - Late Trials
durvalumab
Sensitive
:
B
TMB-H + PD-L1 expression
Urothelial Cancer
TMB-H + PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: B - Late Trials
atezolizumab
Sensitive
:
B
atezolizumab
Sensitive: B - Late Trials
atezolizumab
Sensitive
:
B
APOBEC mutagenesis
Urothelial Cancer
APOBEC mutagenesis
Urothelial Cancer
atezolizumab
Sensitive: B - Late Trials
atezolizumab
Sensitive
:
B
atezolizumab
Sensitive: B - Late Trials
atezolizumab
Sensitive
:
B
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
BT8009
Sensitive: B - Late Trials
BT8009
Sensitive
:
B
BT8009
Sensitive: B - Late Trials
BT8009
Sensitive
:
B
BRCA2 mutation
Urothelial Cancer
BRCA2 mutation
Urothelial Cancer
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
ATM mutation
Urothelial Cancer
ATM mutation
Urothelial Cancer
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
MSI-H/dMMR
Urothelial Cancer
MSI-H/dMMR
Urothelial Cancer
nivolumab
Sensitive: C1 - Off-label
nivolumab
Sensitive
:
C1
nivolumab
Sensitive: C1 - Off-label
nivolumab
Sensitive
:
C1
MSI-H/dMMR
Urothelial Cancer
MSI-H/dMMR
Urothelial Cancer
pembrolizumab
Sensitive: C1 - Off-label
pembrolizumab
Sensitive
:
C1
pembrolizumab
Sensitive: C1 - Off-label
pembrolizumab
Sensitive
:
C1
HER-2 overexpression
Urothelial Cancer
HER-2 overexpression
Urothelial Cancer
trastuzumab
Sensitive: C1 - Off-label
trastuzumab
Sensitive
:
C1
trastuzumab
Sensitive: C1 - Off-label
trastuzumab
Sensitive
:
C1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login